AstraZeneca sells Atacand for $200 million

By
0 mins. to read
AstraZeneca sells Atacand for $200 million
Master Investor Magazine 40 cover

Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

Pharmaceuticals major AstraZeneca (LON:AZN) has agreed to offload the European commercial rights to Atacand and Atacand Plus, a prescription medicine for the treatment of heart failure and hypertension, to Cheplapharm Arzneimittel.

“This agreement forms part of our strategy of streamlining our portfolio of mature medicines to enable reinvestment in our main therapy areas and bringing new medicines to patients,” said AstraZeneca’s executive vice-president of global product and portfolio strategy Mark Mallon.

Cheplapharm is to pay $200 million on completion of the agreement, plus a time-bound payment of $10 million and sales-contingent milestones. In 2017, global product sales for Atacand and Atacand Plus were $300 million, including $86 million in Europe.

Shares in AstraZeneca rose 25p to 5,610p (as at 11:10 BST).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

YOUR FREE INVESTMENT MAG

Get real investment insights from some of the best minds in the business - with our free Master Investor Magazine.